RxDoctor Payments Data

Michael Fusco, MD

Internal Medicine · Stamford, CTNPI 1972516482

Payments from drug & device makers

$380in general payments, 2019–2025

Across 18 payments — averaging $21.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$129
  • GSK$117
  • Novo Nordisk$42
  • Pfizer$40
  • Neurocrine Biosciences, Inc.$31
  • Lilly USA, LLC$22

What the payments were for

  • Food & beverage$380100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)6$129
GSK6$117
Novo Nordisk2$42
Pfizer2$40
Neurocrine Biosciences, Inc.1$31
Lilly USA, LLC1$22

How this compares

$380 in reported general payments places this provider in the 65th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$166,657
Medicare patients
306
Services billed
1,881

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban290$137,034
OzempicSemaglutide64$75,072
JardianceEmpagliflozin55$40,261
JanuviaSitagliptin Phosphate57$38,869
Janumet XrSitagliptin Phos/Metformin Hcl18$25,368
XareltoRivaroxaban31$24,747
EntrestoSacubitril/Valsartan48$20,749
TradjentaLinagliptin61$20,062
JanumetSitagliptin Phos/Metformin Hcl15$16,621
MyrbetriqMirabegron36$16,525
FarxigaDapagliflozin Propanediol14$16,025
GemtesaVibegron12$14,555
VascepaIcosapent Ethyl21$13,829
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$13,005
JentaduetoLinagliptin/Metformin Hcl14$8,490

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$40$137,034290 claims
Novo NordiskOzempic$42$75,07264 claims
GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta$117$22,55339 claims
AbbVieCombigan$129$3,09914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Stamford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →